Humacyte, Inc.
HUMA
$1.39
$0.010.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 6.00% | -37.98% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.00% | -37.98% | |||
| Cost of Revenue | -11.77% | 35.10% | |||
| Gross Profit | 12.12% | -38.38% | |||
| SG&A Expenses | 2.81% | 0.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.22% | 24.50% | |||
| Operating Income | 8.43% | -26.43% | |||
| Income Before Tax | 28.97% | -41.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.97% | -41.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.97% | -41.66% | |||
| EBIT | 8.43% | -26.43% | |||
| EBITDA | 8.96% | -28.96% | |||
| EPS Basic | 32.91% | -20.07% | |||
| Normalized Basic EPS | -59.07% | 51.36% | |||
| EPS Diluted | 32.23% | -20.07% | |||
| Normalized Diluted EPS | -59.07% | 51.36% | |||
| Average Basic Shares Outstanding | 5.92% | 17.98% | |||
| Average Diluted Shares Outstanding | 5.92% | 17.98% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||